The global Non-Invasive Prenatal Testing Market is forecasted to reach USD 8.75 Billion by 2027, according to a new report by Emergen Research. Non-invasive prenatal testing (NIPT), commonly known as cell-free DNA testing, is regarded as a significant extension to the variety of diagnostic methods used to detect fetal chromosome defects. NIPT is also considered superior to other screening modalities, particularly for trisomy 21 (one of the most prevalent congenital anomalies). NIPT enables individuals to make informed decisions as to whether diagnostic testing should be carried out. Associated fetal chromosomal anomalies typically include the benefit or lack of genetic material that can differ from small segments to small segments of chromosomes to entire chromosomes.
The study is a professional probe into the revenue generated and capacity estimates for the Prenatal Testing market for the forecast period 2020 - 2027 empower the business owners to maintain a competitive edge over their rivals. The research further examines and provides data on the market by type, application and geography interspersed with illustrations and other graphical representations. The market analysis not only determines the attractiveness of the industry but also the evolving challenges and opportunities and their association with the weaknesses and strengths of prominent market leaders. Other factors taken into consideration when studying the industry include profitability, manufacturing capability, distribution channels and industry cost structure and major success factors.
North America is believed to lead the global non-invasive prenatal testing market over the forecast period attributable to rising deliveries with genetic defects, demand for innovative screening procedures, and increasing payer reimbursement for the related danger during pregnancies. Annually, an average USD 4,879.0 is expended on child healthcare in the U.S., which is expected to benefit the non-invasive pregnancy testing sector in North America, according to work conducted by the Health Expense Institute. Due to the increasing focus on minimally invasive diagnostic procedures and preference for early detection of illness, the recognition among citizens and expanding healthcare services, Asia Pacific is projected to grow significantly in the global market for non-invasive prenatal research.
The NGS technology, along with cfDNA research, has paved the way for the identification of chromosomal aberrations with growing efficiency and lowering expense. The high-risk testing industry is crowded, and continued rivalry is likely to result in substantial declines in the retail sales price of such tests. The prevalence of such studies can be improved with reduced costs in the market for reproductive genetics. The creation of new technology for NIPT is gradually increasing due to the rising awareness of the advantages of non-invasive methods.
Read more@ https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market
key findings from the report
Based on the method, ultrasound detection generated a revenue of USD 0.86 billion in 2019 and believed to rise with a CAGR of 14.0% in the forecast period, owing to the ability of the ultrasound diagnosis to detect anomalies in the position of the baby and actions within the womb.
The hospital segment expected to grow with a CAGR of 14.1% in the forecasted period due to the growing introduction of non-invasive prenatal testing coupled with rapid technological developments and groundbreaking acceptance strategies.
The trisomy application is the major contributor to the Non-Invasive Prenatal Testing Market. The trisomy application of the North America region is the major shareholder of the market and held around 45.1% of the market in the year 2019, owing to the high incidence of genetic disorders correlated with trisomy’s, such as Patau syndrome, Down syndrome, and Edward syndrome.
North America dominated the market for Non-Invasive Prenatal Testing in 2019 due to the availability of technologically advanced healthcare research system, the region's production of WGS. The North America region held approximately 48.8% of the market, followed by Europe, which contains around 25.4% market in the year 2019.
Key participants include Yourgene Health, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, GE Healthcare, PerkinElmer Inc., BGI, and Natera Inc., among others.
Request For Free Sample@ https://www.emergenresearch.com/request-sample/16
Method Outlook (Revenue, USD Billion; 2017-2027)
Ultrasound Detection
Biochemical Screening Tests
Cell-free DNA in Maternal Plasma Tests
Others
End-Use Outlook (Revenue, USD Billion; 2017-2027)
Diagnostic Laboratories
Hospitals
Research Centers
Clinics
Application Outlook (Revenue, USD Billion; 2017-2027)
Trisomy
Microdeletion Syndrome
Others
Regional Outlook (Revenue, USD Billion; 2017-2027)
North America
Europe
Asia Pacific
Latin America
MEA
Table of Content
Chapter 1. Methodology & Sources
1.1. Prenatal Testing Market Definition
1.2. Prenatal Testing Market Research Scope
1.3. Prenatal Testing Market Methodology
1.4. Prenatal Testing Market Research Sources
1.4.1. Primary
1.4.2. Secondary
1.4.3. Paid Sources
1.5. Prenatal Testing Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Prenatal Testing Market Segmentation & Impact Analysis
Continued…
